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Dizziness is a common condition that is responsible for a significant degree of material morbidity and 
burden on health services. It is usually episodic and short-lived, so when a patient presents to their 
clinician, examination is normal. the CAVA (Continuous Ambulatory Vestibular Assessment) device 
has been developed to provide continuous monitoring of eye-movements, allowing insight into the 
physiological parameters present during a dizziness attack. This article describes the first clinical 
investigation into the medical and technical aspects of this new diagnostic system. seventeen healthy 
subjects wore the device near continuously for up to thirty days, artificially inducing nystagmus on 
eight occasions. 405 days’ worth of data was captured, comprising around four billion data points. 
A computer algorithm developed to detect nystagmus demonstrated a sensitivity of 99.1% (95% 
CI: 95.13% to 99.98%) and a specificity of 98.6% (95% CI: 96.54% to 99.63%). Eighty-two percent of 
participants wore the device for a minimum of eighty percent of each day. Adverse events were self-
limiting and mostly the consequence of skin stripping from the daily replacement of the electrodes. the 
device was shown to operate effectively as an ambulatory monitor, allowing the reliable detection of 
artificially induced nystagmus.
Dizziness is a common, non-specific complaint. In England and Wales, eight out of every 1,000 patients are likely 
to consult with their General Practitioner complaining of dizziness every year1. One in four in the community 
have ‘significant’ dizziness at any given time2. Between 13% and 16% of dizzy patients are referred for a specialist 
opinion; up to 36% of these referrals are to an ENT clinic1,3. Dizziness is the most common reason for a physician 
to visit a patient over the age of 75 years old4, and one-third of adults over the age of 65 years experiences at least 
one fall each year5. A common cause of dizziness is a malfunction in the vestibular system which is located in 
the inner ear6. There is an intimate relationship between eye movements and the inner ear which is mediated 
by a neural reflex called the vestibulo-ocular reflex (VOR), the main purpose of which is to stabilise images on 
the retina during head movements. Because of this relationship, episodes of dizziness caused by inner ear mal-
functions are often accompanied by an abnormal jerking eye movement called nystagmus (Fig. 1). Therefore, eye 
movements are key in assessing the function of the vestibular system7.
The onset of dizziness accompanying vestibular dysfunction is often unpredictable and episodic, making it 
unlikely that an episode of dizziness will coincide with a patient’s visit to a specialist8. Although many traditional 
and contemporary balance tests are available, they only provide a snapshot of vestibular function in the absence 
of an actual ‘dizzy attack’9. Two conditions which attract considerable attention in the clinical and research com-
munities are Ménière’s disease and Vestibular Migraine. The causes of these conditions are not fully understood 
and their assessment is challenging10. Both of these conditions may result in dizziness lasting for many hours, but 
patients may be asymptomatic for days, weeks or even months between attacks. Conditions other than Ménière’s 
disease and Vestibular Migraine can present in an equally sporadic manner.
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The Continuous Ambulatory Vestibular Assessment (CAVA) device is a novel, medical device for recording 
eye movements continuously over a period of thirty days (Fig. 2). The device is composed of two main compo-
nents: a bespoke single-use sensor array that adheres to the participant’s face, and a small, reusable, electronic 
logging unit. The device is lightweight and durable, and can be worn continuously throughout the day and night. 
While worn, the device continuously records horizontal and vertical eye movements and an accelerometer cap-
tures head movement. Eye movements are captured passively by way of the dipole potential (the corneo-retinal 
potential) that exists between the front and the back of the eyeball, which can be used as a proxy for eye move-
ment. CAVA has been developed as part of a program of work funded by the UK Medical Research Council 
to develop a diagnostic system to aid the diagnosis of dizziness. The system itself comprises the CAVA device 
(designed and produced by Wright Design Limited, in Cambridge, UK) and separate computer algorithms for 
detecting short periods of nystagmus contained with days’ worth of normal eye-movement data (developed at the 
University of East Anglia, Norwich, UK).
CAVA is intended to be worn in non-clinical settings by patients suffering from suspected dizzy attacks. At 
the end of a thirty day monitoring period, the data captured by the device would be downloaded and analysed 
offline by computer algorithms for signs of nystagmus. Episodes of dizziness detected by the system would be 
presented to a clinician for further analysis and could be used to support a diagnosis. Nystagmus may be classified 
in a number of ways, including by duration, frequency, beat direction and other characteristics11. Nystagmus 
is divided into a slow and fast phase, corresponding to the eyes drifting slowly in one direction, before quickly 
moving in the opposite direction. The nystagmus shown in Fig. 1 is right-beating, as defined by the direction 
of the fast phase. Using the data captured by the CAVA device, we expect to be able to determine the aetiology 
of dizziness episodes. Whilst peripheral vestibular nystagmus is typically horizontal in nature (or torsional in 
Benign Paroxysmal Positional Vertigo); downbeat and upbeat nystagmus can be identified in a large number 
of conditions from outside the vestibular system12. For example, hyperventilation or intracranial hypotension 
are associated with characteristic forms of nystagmus, such as downbeat nystagmus13–15. Parallels can be drawn 
between the application of the CAVA device and the 24-hour ECG tape that is used to identify cardiac arrhyth-
mias16,17 and ambulatory EEG18–20.
As the CAVA device is an entirely novel device for long-term, ambulatory monitoring, there is little previ-
ous literature with which comparisons can be made. However, a portable recorder for examining nystagmus in 
non-clinical settings was described several decades ago21. The prototype described could record two-channels 
of eye movement for a period of ten minutes, although this was intended to be increased to eighty-minutes in 
Figure 1. A diagram showing right-beating nystagmus induced by watching a left-moving dot on a VR headset. 
The fundamental frequency of the signal shown is 1 Hz. A double-headed arrow marks the waveform period, 
which corresponds to the time taken for the dot to travel once across the headset screen. Examples of the slow 
and fast phases of the nystagmus are indicated by downward and upward pointing arrows.
Figure 2. The CAVA device as it appears when worn on the face. The device comprises a logging unit which sits 
behind the left ear, and five electrode pads which adhere to the face.
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the following version. Owing to the limited data storage, the device was intended to be worn and activated by a 
subject at the onset of an episode of dizziness. Therefore, the device relied on the wearer to correctly identify the 
onset of an attack, and on them being capable of applying the device whilst experiencing symptoms of dizziness. 
The CAVA device represents a significant improvement on that device in terms of the duration of data capture 
and portability. If the CAVA system can detect nystagmus from its ambulatory data, this could pave the way to 
overcome many of the shortfalls of existing approaches to vestibular assessment, potentially reducing the number 
of hospital visits and unnecessary tests, and providing faster diagnoses and access to treatment.
There is much literature addressing the task of automatically identifying nystagmus from short-term 
eye-movement data22–24. However, there is no previous work focused on the analysis of long-term eye-movement 
data, as CAVA is the first device to provide such data. Previous automated approaches have exploited features of 
eye movement which, although well suited to short-term nystagmus classification in laboratory conditions, are 
unlikely to generalise well when applied to days’ worth of highly diverse eye movement data. For example, nystag-
mus detection usually involves identifying saccades (the fast phase of nystagmus) using eye movement velocity. 
A day’s worth of eye-movement data contains vast quantities of normal saccadic eye movement, making reliable 
discrimination more difficult. As the primary objective of this study is to demonstrate that nystagmus can be 
detected from the long-term data captured by the CAVA device, this study poses a significant and novel challenge 
to the field of computer science.
This article describes the first formal clinical investigation undertaken to evaluate the CAVA device in healthy 
volunteers who wore the device for up to thirty days. The primary objective of this investigation was to demon-
strate the diagnostic accuracy of the system to detect artificially induced nystagmus. To meet this objective, 
bespoke computer algorithms were developed to analyse the data offline, in a blinded recognition experiment 
undertaken at the end of the trial. The algorithms were required to demonstrate a diagnostic sensitivity and spec-
ificity of 95% or greater for the task of identifying the dates on which participants induced nystagmus. To recreate 
the nystagmus eye movements produced by dizzy patients, each healthy participant watched a thirty-second 
nystagmus-inducing video on up to eight pre-determined dates. The other aims of the investigation were to eval-
uate device reliability, safety, acceptability and user experience. To meet objectives in these areas, the device had 
to provide less than 5% non-useful data for each participant, for each day of the trial, and across the entirety of 
the trial. The event-marking, timestamping and accelerometer functions of the device had to function correctly. 
Per participant, less than five data drop-outs per day were permitted, and less than sixty across the whole trial. In 
terms of compliance, 80% of participants were required to comply for a minimum of 80% of the complete trial, 
and for a minimum of 80% of each day. There were no objectives associated with user experience and safety, but 
the data is presented for clarity and a qualitative analysis is provided. Following the completion of this trial, we 
intend to undertake a second investigation involving patients suffering from vertigo.
Methods
study design. This study was a single-arm, blinded, clinical investigation undertaken at the Norfolk and 
Norwich University Hospital, in the United Kingdom. Nineteen healthy participants were screened and the 
CONSORT diagram in Fig. 3 shows the flow of participants through the trial. The primary aim of this study was 
to show that short periods of artificially induced nystagmus could be detected from within days’ worth of normal 
eye movement data captured by the CAVA device. The study was registered on clinicaltrials.gov (NCT03661762) 
on 7th September 2018. The Medicines and Healthcare products Regulatory Agency (MHRA) was notified of 
the investigation, who reviewed and approved the trial. All trial processes and trial documentation, including 
the protocol, were reviewed and approved by the London-Dulwich Research Ethics Committee (IRAS: 240847). 
The study was carried out in accordance with the relevant guidelines and regulations. A recruitment target of 
fifteen participants and a minimum number of positive samples (dates containing nystagmus) were determined 
by a medical statistician (see Statistical Analysis section). Prior to the start of the trial, the first participant was 
designated as a dry-run. The dry-run participant would be excluded from the final, blinded analysis, and would 
provide the opportunity for refinements to be made to the device and trial processes in the event that any minor 
operational issues were encountered.
The study was designed around a blinded nystagmus-recognition task, in which bespoke computer algorithms 
for detecting nystagmus were applied to the data captured during the trial. As this was a healthy volunteer trial, 
participants did not experience episodes of dizziness. To simulate dizziness, each participant induced physio-
logical, horizontal nystagmus by watching a video on a portable screen. Participants were expected to wear the 
device for thirty days, and were instructed to induce nystagmus on eight occasions. At the end of the trial, the 
data captured was downloaded, randomised (See section Data Randomisation, Blinding and Analysis) and then 
computer algorithms were applied to the data to detect the dates on which nystagmus was induced (See section 
Nystagmus Detection Algorithm). In addition to this, data relating to device reliability, participant compliance and 
user experience were captured during the trial.
Figure 3. Consort diagram showing the flow of study participants through the trial.
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Healthy individuals were recruited through a poster campaign at the University of East Anglia, in the United 
Kingdom. Participants were recruited according to availability and no sampling of the population took place. 
The population of potential participants consisted primarily of university-age students and also of working-age 
university staff. Potential participants approached the study team and were provided with an information sheet 
detailing the requirements, benefits and risks of participation in the study. Interested participants attended a 
consenting visit at the hospital, where informed consent was obtained for all participants. Once consented, eligi-
bility criteria were checked (see Inclusion and Exclusion Criteria section), and successfully screened participants 
were enrolled onto the trial. Participants were trained regarding all trial procedures, and were provided with one 
device and enough single-use electrode mounts to replace them daily, for thirty days. Participants were allotted 
one hour each day to shower and to renew the electrode mounts. The electrodes contained within the mounts 
were the Covidien Kendall H124SG electrodes, which are small ECG/EMG electrodes. Each device was activated 
prior to the participant leaving the clinic, and it recorded data continuously until deactivated by a member of the 
study team at the end of the trial.
Participants returned to the hospital on day five to make sure that they were not experiencing any difficulties, 
and that they had not experienced an allergic reaction to the materials in the electrode pads. On day thirteen, 
participants returned so that the device’s battery could be renewed and to perform an interim data download. The 
device’s event marker was also pressed during this visit, providing data to allow the device’s timestamping and 
event marking functions to be assessed at the end of the trial. The final return visit was on day thirty-four, when 
they returned the device and were debriefed from the trial.
During the final visit, participants completed a short questionnaire, designed to gather feedback on the device 
and the trial. The questionnaire comprised ten questions, with eight requiring scale-based responses, and two 
requesting a written comment. Space was provided for participants justify all ratings given. Participants also 
performed a series of head movements, designed to assess the functionality of each device’s accelerometer. Three 
separate head movements were performed, at both a slow and a fast speed.
On eight occasions during the trial, each participant induced physiological, horizontal nystagmus by watching 
a video on a portable screen. Each participant was randomly allocated one of six videos. The selection of videos 
included three different speeds of moving dot, and the dots either moved in a leftward or rightward direction. 
Participants watched the video whilst remaining stationary for the first four days, and whilst walking gently 
on the spot for the remaining four days. Prior to watching the video, participants were instructed to press the 
event marker button on the CAVA device, which added a timestamped annotation to the device data. This anno-
tation was used by a member of the study team to verify that the video had been viewed (See section Data 
Randomisation, Blinding and Analysis). After the trial, the horizontal eye movement data was extracted, ran-
domised and then a blinded investigator used bespoke computer algorithms to predict the presence or absence 
of nystagmus in each day’s worth of data. The eye movement data from the first participant (dry-run) were not 
included in the final, blinded recognition task. The sensitivity and specificity of the algorithm’s predictions were 
determined by a medical statistician using the number of true positive, false positive, true negative and false 
negative detections.
Inclusion and exclusion criteria. Inclusion criteria were healthy volunteers who were (a) aged 18 and over 
(b) were able to commit to thirty days of continuous wear of the trial device (c) owned a telephone. Exclusion cri-
teria were (a) potential participants who had a history of dermatological disease or damage around the forehead 
(b) potential participants who had an allergy to plasters and/or medical adhesives (similarly to materials used in 
the device) (c) a history of dizziness, vertigo, balance disorders, or syncope (d) history of hypertension or cardiac 
problems (uncontrolled, acute or de-compensated phase) (e) history of ear disease, or previous ear surgery (f) 
history of psychotic/neurotic disorders or epilepsy (g) history of eye disease, or previous eye surgery (h) pregnant 
or nursing mothers (i) unable to follow the testing protocol.
Data randomisation, blinding and analysis. At the end of each participant’s trial, the data from their 
device was downloaded by the research team. None of the device data contained participant identifiable infor-
mation. The data was first converted from the compact representation used during storage to a human readable 
format (A Microsoft Excel compatible file). Each participant’s data was re-segmented into thirty full calendar 
days’ worth of data and the data from a single day constituted a file. Only the data corresponding to the horizontal 
eye movement was retained, and all other data was discarded, including the event marker data. The first and last 
days of the trial (days one and thirty-one) were half days, and the data from these days were combined to approx-
imate one full day. Multiple data files within a single day were also combined (e.g. on day thirteen, resulting from 
the battery change). Finally, re-segmentation also adjusted for Daylight Saving. Once resegmented, the data was 
uploaded to a secure server at the University of East Anglia.
The unblinded investigator was responsible for randomising the trial data and for maintaining the blinding 
from the blinded investigator. Before randomisation, the unblinded investigator manually reviewed the trial data 
for evidence that the device had recorded an informative signal (i.e. not simply a flat line), and also examined the 
signals for evidence of the characteristic nystagmus waveform on the dates and times logged in the participant’s 
trial diaries and using the event marker data. Based on these observations, each file was assigned a label indicating 
the presence of absence of nystagmus in the file (the ground-truth label).
After labelling, the unblinded investigator assigned each of the individual days a randomised filename. Using a 
coding sheet, only the unblinded investigator was able to determine the origin (participant ID and date) for each 
of the randomised files. The data was then analysed offline by the blinded investigator, using a specially-designed 
computer algorithm (see Nystagmus Detection Algorithm section). This algorithm produced a list of files pre-
dicted to contain a horizontal nystagmus signal, and corresponding values of the signal’s beat direction and beat 
frequency. The unblinded investigator compared the predicted dates from the algorithm with the ground-truth 
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dates in the coding sheet. Finally, the results were analysed by the project’s designated medical statistician to 
determine the diagnostic accuracy of the results obtained. This analysis consisted of calculations of sensitivity and 
specificity, as described in the Statistical Analysis section. The blinding was formally lifted once the final analysis 
was complete.
Nystagmus detection algorithm. A nystagmus detection algorithm was developed to detect automati-
cally the periods of horizontal nystagmus contained within the trial data. The system used to analyse the trial data 
employed an ensemble of machine learning techniques, built using frequency domain recognition features, and 
consisting of a multi-stage recognition process in which potential nystagmus candidates were accepted or rejected 
based on several heuristic metrics.
For feature extraction, a Fast Fourier Transform (FFT) was used to transform the time series data into the 
frequency domain. The data was processed using a sliding window with an 80% overlap and a window length 
of 500 samples, producing frames representing the positive frequency amplitudes. 82 points of the FFT were 
retained, corresponding to frequencies between 0.25 Hz and 7 Hz, spaced at 0.083 Hz intervals. These parameters, 
and others used in the system, were selected based on experiments on preliminary data recorded prior to the trial.
Three separate machine learning classifiers were trained using the features derived from the training data: A 
Support Vector Machine (SVM)25, a Linear Discriminant Analysis transformation (LDA)26 and an ensemble clas-
sifier of boosted trees27. These classifiers were trained to identify nystagmus, irrespective of direction and speed. 
During testing, the outputs of these classifiers were combined by way of a majority voting system, and the output 
was smoothed using a sieve filter28. Combining the classifier outputs in this way, often referred to as an ensemble 
of classifiers, has been shown to be an effective approach to time series classification29.
Lastly, a validation step occurred on each run of consecutive frames classified as nystagmus. In this step, 
Dynamic Programming (DP) was used to compare the time series signal to a sawtooth waveform. The output of 
this process was a value that quantified the degree to which the eye movement signal matched a sawtooth wave-
form. Any data file containing positively classified frames was considered as a positive detection of nystagmus. 
Each detected nystagmus event was further classified according to its beat direction and beat frequency.
To classify the nystagmus beat direction, the velocity signal was calculated from the time series waveform, as 
the velocity of the signal provides useful information which can be used to determine the beat-direction of the 
nystagmus. For example, the slow phase of a normal sawtooth wave contains mostly negative velocities, while for 
a mirrored sawtooth, the signs are inverted. Each frame was assigned a weighting (between −1 and 1) reflecting 
the proportion of negative and positive velocities. The average weighting within the event was used to classify the 
direction of the nystagmus. For the classification of nystagmus frequency, the FFT was calculated for each event. 
From the FFT output, the modal frequency bin was identified, and the frequency of the nystagmus was classified 
as the closest class to that bin. In the case of a tie between bins, the highest neighbouring bin was found and the 
decision was based upon that frequency instead.
statistical analysis. The success of a diagnostic device to diagnose disease can be appraised by calculating 
values for sensitivity and specificity. This trial has been designed to exceed the minimum number of nystagmus 
days and minimum number of total days required to demonstrate with statistical significance a sensitivity and 
specificity of over 95%. This standard was determined from data in the field of ambulatory cardiac monitoring30. 
The calculations below were performed by a medical statistician to determine the minimum number of inde-
pendent tests for the nystagmus detection algorithms to demonstrate the required level of diagnostic sensitivity 
and specificity.
In the usual way, we define:
Sensitivity = (# days on which nystagmus was detected and present)/(# days on which nystagmus was detected)
Specificity = (# days on which nystagmus was not detected and not present)/(# days on which nystagmus was 
not detected)
Each file was a day’s worth of data and contained either zero or one nystagmus event. We assumed independ-
ence of these events as the data was randomised prior to analysis. The primary objective for our algorithm was to 
demonstrate a sensitivity >95% and a specificity >95% at a confidence level of 95%. For a mean sensitivity and 
specificity of 98% with a maximum marginal error of 3%, for constructing the 95% confidence interval (0.9442 
to 1.000), a sample size of 85 positive and 85 negative events is required (Table 1). In practice, we recorded 112 
positive events and 293 negative events.
Device Prediction
TotalTRUE FALSE
Ground-truth
TRUE 83 (97.7%) 2 (2.3%) 85
FALSE 2 (2.3%) 83 (97.7%) 85
Total 85 85 170
Table 1. Minimum number of positive and negative samples required to demonstrate a sensitivity and 
specificity of over 95%.
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Results
Nineteen participants were screened and eighteen participants were enrolled onto the trial. One participant failed 
screening as they were unable to follow the training protocol. One participant was withdrawn having worn the 
device for less than twelve hours, as it became apparent that they were unable to adhere to the trial protocol. For 
this reason, we have excluded this participant from all further analyses, giving a total of seventeen participants 
analysed. Of these seventeen participants, seven withdrew before completion of the full trial (see Compliance sec-
tion). The first participant was recruited as a dry-run participant, allowing the device to be evaluated in full prior 
to deployment of the remaining participants. There were no deviations from the trial protocol which could have 
affected the scientific value of the study. A summary of the demographics of the study participants is presented 
in Table 2. A broad range of ages were recruited, which is likely to be consistent with the distribution of ages 
present in a university population of staff and students. Nearly twice as many females than males were recruited. 
This was not by design, and appeared to be due to the increased willingness of females to volunteer for the study. 
The following sections report the results of the trial in the areas of diagnostic accuracy, device reliability, safety, 
acceptability and participant feedback.
Diagnostic accuracy. Each day of data captured from a participant was either a “non-nystagmus” day or a 
“nystagmus” day, determined by whether or not the subject had induced nystagmus on that day. A computer algo-
rithm used to identify the nystagmus days achieved a detection sensitivity of 99.1% (95% CI: 95.13% to 99.98%) 
and a specificity of 98.6% (95% CI: 96.54% to 99.63%), when applied to the randomised trial data (see Statistical 
Analysis section for definitions of sensitivity and specificity). Table 3 provides the classification results of this task 
in terms of true positive, false positive, true negative and false negative detections. The single false negative was 
found to contain a noise impulse in the nystagmus signal, caused by the participant pressing the device’s event 
marker button midway through inducing nystagmus. The false positives were found to generally be periodic in 
nature, and observation of the concurrent accelerometer data showed that they might be due to physical activities 
such as running on a treadmill.
A more detailed recognition task was conducted on the 111 correctly identified nystagmus events (Tables 4 
and 5). This analysis included the classification of nystagmus beat direction and frequency. Nystagmus beat 
Characteristic Value (n = 17)
Age (yrs.)
18 to 25: 6 26 to 35: 5 36 to 45: 3
46 to 55: 2 56 to 65: 1
Gender (frequency) Male: 6 Female: 11
Table 2. Demographics of the participants enrolled in the CAVA: Healthy Volunteer Trial.
Ground Truth
TotalPresent Absent
Predicted
Present 111 4 115
Absent 1 289 290
Total 112 293 405
Table 3. Confusion matrix for the nystagmus detection task.
Ground Truth
TotalLeft Right
Predicted
Left 52 1 53
Right 0 58 58
Total 54 61 111
Table 4. Confusion matrix for the classification of beat direction.
Ground Truth
Total0.8 Hz 1.0 Hz 1.2 Hz
Predicted
0.8 Hz 35 1 0 36
1.0 Hz 0 35 1 36
1.2 Hz 0 0 39 39
Total 35 36 40 111
Table 5. Confusion matrix for the classification of beat frequency.
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direction is defined by the direction that the eyes move during the fast phase. For the task of classifying beat 
direction, an accuracy of 99.10% (one incorrect classification) was attained. For the three-class recognition task of 
classifying the fundamental beat frequency, the accuracy was 98.20% (two incorrect classifications). These values 
indicate that, using data captured by the CAVA device, a minimum duration of thirty seconds of visually-induced 
nystagmus can be identified automatically with a high degree of accuracy, including some more detailed charac-
teristics of the associated waveforms.
Hardware reliability. The majority of trial participants (12 of 17) experienced no technical difficulties or 
hardware issues relating to the use of the CAVA device. No issues were reported relating to battery life or device 
usability. The device’s event marking function was found to operate as expected, but each device displayed a 
timestamping clock drift of up to twenty-one minutes per day. This drift is a small issue relating to the labelling of 
the data, and did not cause any loss of device data.
The devices’ accelerometers functioned as intended, with nearly all head movements being easily discernible 
from the data captured. However, identification of head turning was slightly reduced compared to the other 
head movements, perhaps due to the staged nature of the task (sitting upright in a chair, in a clinical setting) and 
because this motion is predominantly rotational, rather than accelerative along a linear axis.
During the first participant’s trial (dry-run), an issue was identified relating to the cable for the right-hand 
electrode mount. Due to compression of the cable during sleep and the repeated reapplication of the device, the 
cable could twist over time, compromising the device’s internal solder joints. This issue caused a data drop-out 
lasting approximately three hours. Following discovery of this issue, a mechanical fix was implemented on all 
devices, and it did not re-occur.
In total, four technical issues arose during deployment of the remaining participants. One participant reported 
that their device was sporadically indicating a possible “lead-off event” (device not properly attached to the face). 
This participant was advised to apply a new set of mounts, which resolved the issue. Inspection of the mounts 
that were removed revealed that a single solder point had failed. This issue caused a sporadic loss of vertical eye 
movement data, but all other data was intact. This issue occurred only once.
Three malfunctions occurred leading to a short-term data drop-out. One participant reported that their device 
was permanently displaying an error status. A software error was found to have occurred, causing the device to 
stop logging. The device was repaired and then resumed normal functioning. Another participant reported a 
similar issue, but around nine hours after they had stopped wearing the device due to skin issues. Lastly, a partici-
pant reported that, having reapplied their device, it was unresponsive to button presses. This device was restarted 
and resumed logging. All data captured during the trial was useful, providing valuable information about eye and 
head movement. The maximum number of drop-outs per day was one, with three occurring in total, reported by 
three separate participants (following the dry-run). These values are within the maximum limits for non-useful 
data and drop-outs as specified in our trial objectives.
Acceptability. Ten participants completed the thirty day trial in full, and all ten wore the device on every full 
day of their trial. Figure 4 displays the compliance per participant, shown as the number of calendar days com-
pleted before withdrawal from, or completion of the trial. Each participant was expected to wear the device across 
thirty-one calendar days, applying it for the first time in the morning of day one and removing it for the final 
time on day thirty-one. The mean trial duration across participants was twenty-seven days (excluding participant 
thirteen and taking the full trial duration to be thirty days).
Seven participants withdrew prior to day thirty-one. Of these seven, one participant was asked to withdraw 
having revealed that they met one of the trial’s exclusion criteria. The remaining six participants withdrew because 
of the onset of skin issues resulting from the use of the device’s electrodes (see Safety section). Of the six partici-
pants who withdrew because of skin issues, all complied fully up to the point that they were withdrawn through 
mutual agreement with the study team (three participants), or withdrew prior to contacting the project team 
(three participants).
Figure 4. Trial compliance per participant, up to and including completion or withdrawal.
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Daily compliance was calculated using the participants’ trial diaries (Supplementary Fig. S1). For these cal-
culations, a day was taken as twenty-three hours, as participants were allowed to remove the device for an hour 
each day in order to shower. 82% of participants (14 of 17) complied for more than 80% of each day. 90% (9 of 10) 
who completed the trial in full, were fully compliant for each day of the trial. In cases where compliance was not 
full, participants had removed the device because of the onset of skin issues or had been instructed to remove it 
by the study team.
safety. Seven unique adverse events were reported during the trial, two of which were unrelated to the device, 
and one of which (disturbed sleep) was tolerated by the participant who reported it. The remaining four adverse 
events were related to the onset of a self-limiting skin issue resulting from near-continuous wear of the device’s 
electrode pads. Of the seventeen participants analysed, nine (53%) experienced a degree of skin reddening. Of 
these nine participants, six (67%) withdrew from the trial as a result of the reddening, and three were able to con-
tinue by repositioning the electrode sites to avoid the affected skin. Two of the nine participants (22%) revealed 
a history of dermatological disease after the reddening had started. The project’s designated dermatologist pro-
posed that this issue was an exaggerated form of the appearance one would expect to see in an individual who 
repeatedly reapplied a sticking plaster. The cause was hypothesized to be a combination of the trauma of electrode 
removal and the long-term occlusion of the skin. One participant experienced an allergic reaction to the materials 
in the electrode pads.
Reporting of skin redness was always delayed, and was therefore correlated with wear duration and the fre-
quency of pad replacement. The first participant (dry-run) reported reddened skin on day four, and following 
this, subsequent participants were provided with a medical adhesive remover, to ease removal of the electrodes. 
Of the remaining eight participants who experienced a skin issue, seven reported redness on or after day nineteen 
and the minimum duration before reporting increased to thirteen days. These results suggest that the adhesive 
remover may have delayed the onset of skin related issues. The issue was self-limiting and resolved quickly and 
fully once the participants had stopped reapplying the device. No serious adverse events were reported during 
the trial.
participant Feedback. Each participant who completed the full trial completed a questionnaire designed 
to gather feedback on their experiences during the trial (Supplementary Fig. S2). Analysis of their responses 
revealed largely positive feedback (Fig. 5). In terms of device usability, all participants found the device to be both 
Figure 5. Trial questionnaire results. Only participants who completed the trial in full were asked to complete 
the questionnaire.
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easy to apply and to remove from the face (Fig. 5a,b). The majority of participants found it easy to sleep whilst 
wearing the device (c). Participants generally found the device to be comfortable to wear (d), with some reporting 
more discomfort from the device sitting over the ear (e). With respect to the social implications of wearing the 
device, all participants reported that the device did not interfere greatly with their normal daily activities (f), and 
that they were generally unaware of the device during an average day (g). A majority said that they did not feel 
self-conscious whilst wearing the device (h).
Discussion
This is the first investigation of a novel, ambulatory device for recording eye movements over a period of thirty 
days. As such, the data collected and results obtained are equally novel. Early work into similar technology 
was limited by the capability of technology at that time21. Specifically, previous attempts were bulky, restricted 
the wearer’s vision, and did not offer sufficient data storage to be used as a long-term, ambulatory device. 
Advancements in computer processing, data storage, device miniaturisation and battery life have allowed the 
development of a highly portable device which can record vast amounts of information. The usefulness of the data 
captured is demonstrated by the ability of our computer algorithms to attain high levels of diagnostic accuracy 
for the task of identifying short periods of visually-induced nystagmus from within days’ worth of normal eye 
movement data (99.1% sensitivity and 98.6% specificity). The algorithms were also able to distinguish between left 
and right-beating nystagmus, and different speeds of nystagmus, with similarly good results.
The device was shown to be very reliable, with only a handful of technical issues arising during 405 days of 
deployment. Two of the issues that arose were the result of simple mechanical failures, which were easily repaired. 
The other issues were related to device software, and were easily overcome by restarting the logging-unit. The 
device’s status-checking functionality proved vital to the early identification of these issues, and helped to mini-
mise the duration of the resulting data drop-outs. The ancillary functions of the device, such as the accelerometer, 
event marking and timestamping, were shown to function as intended, although the accuracy of the timestamp-
ing was inadequate. The cause of this software issue has since been identified and rectified. In summary, the device 
has fulfilled the trial objectives which included the maximum amount of non-useful data and the number of data 
drop-outs permitted during the trial, as well as the correct functioning of the device’s accelerometer and event 
marker.
Participant compliance throughout the trial was generally high, meeting the trial objectives, and was only 
reduced by the onset of skin issues arising from the specific choice of electrode pad used by the CAVA device. 
All participants who withdrew expressed a desire to continue, and up until withdrawing, individual participant 
compliance was extremely high. Participants who completed the trial in full provided generally positive feedback 
regarding their experiences of wearing the device.
During the trial, a minor safety issue was identified relating to the long-term wear and repeated replacement 
of the device’s electrode pads. As stated above, this issue resulted in several participants withdrawing prematurely 
from the trial. Following discussions with the CAVA device’s manufacturer, medical experts and electrode pad 
manufacturers, we have concluded that the issues were mostly caused by skin stripping, as would be expected after 
the repeated removal of a sticking plaster. Prior to the start of the trial, we held a patient engagement event, where 
we gathered feedback from patients on their experiences of suffering from extended periods of dizziness. The 
feedback gained from that event suggested that such patients may have a particularly high tolerance to discom-
fort, due to the severity of the symptoms they frequently endure. Therefore, it is reassuring that real patients may 
consider this to be an issue of secondary importance. No adverse events were reported related to the safety of the 
device itself, providing confidence that the CAVA device is otherwise safe to wear.
Limitations of the study. The computer algorithm applied to the trial data has demonstrated that the fun-
damental frequency of nystagmus (i.e. the number of nystagmus beats per second) can be accurately measured 
from the CAVA data. In isolation, this is of limited clinical use, as the Slow Phase Velocity (SPV) is the preferred 
method used by clinicians to quantify nystagmus. The SPV provides a measure of the speed of eye movement in 
degrees per second. In order to do this calculation, ocular excursions have to be measured in degrees, which cur-
rently CAVA does not do. The corneo-retinal potential (CRP) recorded by the CAVA device requires calibration 
to relate it to an absolute position in degrees. The CRP has shown to be influenced by many factors, including light, 
fatigue and diurnal rhythm31, and therefore, robust methods of normalising for these differences would have to be 
developed to allow this association to be made.
While this study does represent a significant advance in the development of the CAVA device, the device itself 
is currently an advanced prototype. A significant amount of work will be required to develop it from a research 
tool to a system which could be routinely deployed among real patients in primary or secondary care. Here, we 
have demonstrated that the system can identify horizontal nystagmus which has been induced visually, but iden-
tifying the aetiology of dizziness will also require the identification of up- or downbeat nystagmus, and nystagmus 
resulting from actual vestibular conditions and other causes. The eye-in-orbit position may also be less consistent 
when observing real dizzy attacks, as patients are known to vary their gaze in order to reduce the severity of their 
dizziness32, and the effects of this on diagnostic accuracy are currently unknown. We have no reason to suspect 
that vertical eye movements are not captured at a similar level of detail to horizontal movements, and shortly we 
will address these points by way of a further trial in dizzy patients (See Future Work).
Implications for the future. The results described here have several implications for both the medical and 
scientific communities. Firstly, the ability to detect nystagmus provides a promising indication that the cause 
of a patient’s dizziness may be determined from data captured by the CAVA device. At the highest level, the 
absence of nystagmus would suggest a cause not of vestibular origin. The long-term data captured by the CAVA 
device has never been observed before. When applied to patients suffering from dizziness, it is possible that 
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the characteristics of the nystagmus captured may provide sufficient information to assist with the diagnosis of 
distinct conditions, and may also allow sub-typing, staging, the determination of disease severity, and the mon-
itoring of treatment responses. The detection algorithm used here has already shown to be able to distinguish 
between left and right-beating nystagmus, a feature of nystagmus which, in patients suffering from dizziness 
caused by inner ear malfunctions, can suggest the affected ear. A device such as CAVA, if routinely deployed in 
clinical care, would lead to swifter and more accurate diagnoses, faster access to more accurate treatments, and 
would reduce unnecessary investigations and consultations.
The data captured during this trial is believed to be the largest dataset of eye movement data ever captured. 
As well as facilitating further development of our computer algorithms, this data may also be of interest within 
the areas of sleep analysis and activity detection. The CAVA device also has the potential to provide insight into 
many medical conditions other than those related to dizziness, such as stroke and sleep medicine, and as such, the 
device could be used to capture new data in these areas.
Future work. To further investigate the mechanism of skin trauma and to identify a solution to this safety 
issue identified during the trial, we have recently started a new trial in which we intend to explore the safety of 
alternative electrode pads and possible alternatives to the current pad replacement regime. We have identified a 
number of alternative electrode pads, including some with hypoallergenic electrodes that contain a ‘breathable’ 
fabric, and using either a wet or a solid hydrogel. Furthermore, we intend to explore whether increasing the dura-
tion of wear (i.e. replacing the electrodes less frequently) delays the onset of skin reddening.
Having demonstrated the capability of the device on healthy volunteers, we are also preparing to undertake 
a further trial on patients suffering from dizziness and vertigo. By deploying the device on such patients, we will 
collect a wealth of dizziness data which will evaluate the CAVA device’s capability to capture a wider range of 
nystagmus signals, as well as continuing to evaluate nystagmus detection accuracy, reliability, acceptability and 
safety. The data we intend to capture may also provide insight into the varying patterns of nystagmus presented by 
the different dizziness conditions, which have not been systematically observed hitherto.
Conclusions
The CAVA device was worn by seventeen participants for up to thirty days, who in total captured around 
9000 hours of eye and head movement data, totalling 405 days’ worth of data. In this trial, we have evaluated a 
fully functional medical prototype in a rigorous and challenging manner; our device performs continuous ambu-
latory monitoring in a non-clinical setting, with minimal intervention from medical or scientific professionals. 
The data captured by the device was successfully used to identify short periods of visually induced nystagmus 
with a high degree of diagnostic accuracy. The device was reliable, functioned well as an ambulatory monitor and 
was tolerated well by the trial participants. Aside from a minor issue related to the repeated removal of the device’s 
electrode pads, the device was found to be entirely safe. The success of this trial has proven the potential of this 
system to Fulfil a demonstrated clinical need, and for establishing a new field of medicine; vestibular telemetry. 
These results have provided a good foundation from which to conduct a further study intended to evaluate the 
system’s diagnostic accuracy among real dizzy patients.
Data Availability
The dataset generated by this study is available from the corresponding author on reasonable request.
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